MoonLake Immunotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of MoonLake Immunotherapeutics generated cash of -$42,778,167, which is more than the previous year. Cash used in financing activities reached the amount of $479,701,508 last year. Net change in cash is therefore $411,663.
Cash Flow
| 2020 | -316.69K | -115M | 116.65M |
|---|---|---|---|
| 2021 | -35.17M | -50.71K | 43.26M |
| 2022 | -55.89M | -32.34M | 119.69M |
| 2023 | -42.77M | -25.18M | 479.70M |
MLTX Cash Flow Statement (2020 – 2023)
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
Cash at beginning of period | 39.50M | 8.03M | 1.33M | 0 |
Operating activities | ||||
Net income | -44.07M | -64.50M | -53.64M | -90.83K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||
Depreciation and amortization | 13.15K | 12.35K | 4.97K | 0 |
Stock-based compensation expense | 7.10M | 9.65K | 10.86K | 0 |
| Deferred income tax benefit | 7.10M | 9.65K | 10.86K | 0 |
| Changes in operating assets and liabilities: | ||||
Accounts receivable, net | 0 | -68.35K | -148.77K | 0 |
Inventories | 0 | 0 | 0 | 0 |
Accounts payable | 0 | -1.31M | 1.56M | 0 |
Cash generated by operating activities | -42.77M | -55.89M | -35.17M | -316.69K |
Investing activities | ||||
Purchases Of Investments | -175.73M | -42.22M | 0 | -115M |
Investments In Property Plant And Equipment | -284.63K | -16.00K | -50.71K | 0 |
Acquisitions Net | 0 | 32.32K | 0 | 0 |
Cash generated by investing activities | -25.18M | -32.34M | -50.71K | -115M |
Financing activities | ||||
Common Stock Issued | 482.45M | 3.79K | 28.26M | 117M |
Payments for dividends | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -6.20K | 0 |
Repayments of term debt | 0 | -15M | -15M | 0 |
Cash used in financing activities | 479.70M | 119.69M | 43.26M | 116.65M |
Net Change In Cash | 411.66K | 31.46M | 6.70M | 1.33M |
Cash at end of period | 451.16M | 39.50M | 8.03M | 1.33M |
| Data source | Data source | Data source | Data source |